Source | Setting | Exclusion | Patients (M/F)/circuits, number | Mean age, years | Severity | Modality; dilution; blood flow (ml/min) | Filter material |
---|---|---|---|---|---|---|---|
Stucker et al. [11] (2015; CH) | ICU of the university hospitals | Cirrhosis, severe coagulopathy, high risk of bleeding and sensitivity to heparin | C: 54 (32/22)/NR | C: 60 ± 14a | C: 28 ± 9 (APACHE II)/63 ± 18 (SAPS)a | CVVHDF; 2/3 pre-dilution and 1/3 post-dilution; 100–200 | 1.5 m2 High-flux membrane |
H: 49 (32/17)/NR | H: 65 ± 16a | H: 29 ± 9 (APACHE II)/65 ± 18 (SAPS)a | |||||
Gattas et al. [12] (2015; AU) | Seven different ICUs | Liver failure, pregnant or breastfeeding, HIT, chronic dialysis | C: 105 (74/31)/390 | C: 66.4 ± 14.3a | C: 25.6 ± 7.6 (APACHE II)a | CVVHDF (61 %) CVVH (29 %); pre-dilution; 150 (52 %) 200 (23 %) | Aquarius or Prismaflex |
H: 107 (72/35)/467 | H: 66.8 ± 14.9a | H: 25.0 ± 6.9 (APACHE II)a | |||||
Schilder et al. [13] (2014; NL) | Ten different ICUs | High bleeding risk, other Therapeutic anticoagulation, HIT | C: 66 (44/22)/NR | C: 67 (36–87)b | C: 23 (11–53) (APACHE II)/10 (2–19) (SOFA)b | CVVH; pre-dilution; 180 | NR |
H: 73 (49/24)/NR | H: 67 (23–85)b | H: 25 (6–43) (APACHE II)/11 (3–18) (SOFA)b | |||||
Brain et al. [25] (2014; AU) | A large metropolitan ICU | Contraindication to citrate or heparin, pregnancy, or lactation | C: 19 (12/7)/96 H: 11 (7/4)/125 | C: 64 ± 13a H: 51 ± 17a | C: 80 (58–99) (APACHE III)b H: 61 (52.5–91.5) (APACHE III)b | CVVHDF; pre-dilution; mean 191 (citrate) and 217 (heparin) | ST-100 (68.8 %); ST-150 (7.2 %); M100 (20.8 %); others (3.2 %) |
Monchi et al. [27] (2004; BE) | 32-Bed medical and surgical ICU | Cirrhosis, severe coagulopathy, high risk of bleeding | C: 8 (NR)/26 | C: 67 (52–77)b | C: 40 (31–53) (SAPS)b | CVVH; post-dilution; 175 | 1.6 m2 Highly permeable PS membrane |
H: 12 (/NR)/23 | H: 64 (52–74)b | H: 42 (33–55) (SAPS)b | |||||
Lin XM et al. [29] (2007; CN) | Adult mixed ICU | NR | C: 27 (16/11)/NR | C: 63 ± 21a | C: 82.5 ± 22.4 (APACHE III)a | CVVHDF; pre-dilution; 100–180 | PRISMA M-100 AN69 |
H: 23 (14/9)/NR | H: 64 ± 19a | H: 75.6 ± 18.3 (APACHE III)a | |||||
Cui W et al. [30] (2011; CN) | Adult mixed ICU | NR | C: 23 (12/11)/NR | C: 46.9 ± 6.1a | C: NR | CVVH; NR; NR | PRISMA |
H: 23 (13/10)/NR | H: 47.2 ± 5.9a | H: NR | |||||
Yang ST et al. [31] (2014; CN) | Adult mixed ICU | severe coagulopathy, high risk of bleeding | C: 25 (NR)/81 | 61.7 ± 8.6 | C: NR | CVVH; pre-dilution; 200–250 | Aquarius, HF1200 |
H: 21 (NR)/53 | H: NR | ||||||
Oudemans-van Straaten et al. [28] (2009; NL) | ICU of a teaching hospital | Cirrhosis, bleeding, HIT, chronic dialysis, Contraindication to citrate or heparin | C: 97 (66/31)/NR | C: 73 (67–79)b | C: 28 (27–30) (APACHE II)/59 (55–62) (SAPS)b | CVVH; post-dilution; 220 | 1.9 m2 Cellulose triacetate hollow fibre membrane |
N: 103 (70/33)/NR | N: 73 (67–79)b | N: 8 (27–29) (APACHE II)/61 (58–64) (SAPS)b | |||||
Betjes et al. [24] (2007; NL) | Adult mixed ICU | HIT, severe coagulopathy, high risk of bleeding, severe circulatory shock and liver failure | C: 1 (15/6)/70 | C: 57.8 ± 4.2a | C: 51.4 ± 4.1 (SAPS)a | CVVH;post-dilution; 150 | High-flux triacetate |
H: 27 (19/8)/72 | H: 55.2 ± 2.8a | H: 51.0 ± 2.6 (SAPS)a | |||||
Fealy et al. [26] (2007; AU) | ICU of tertiary hospital | Liver failure, hepatitis and contraindication to citrate or heparin | C:10 (9/1)/10 | 71 (63.5–76.5)b | SAPS: 41 (31–43) APACHE II:17 (15–21)b | CVVH; pre-dilution; 150 | APS650 PS hollow fibre membrane |
H:10 (9/1)/10 | |||||||
Kutsogiannis et al. [34] (2005; CA) | Tertiary and community hospital ICU | Liver failure, Contraindication to citrate or heparin | C: 16 (7/9)/36 | C: 66.5 ± 14.5a | C: 7.75 ± 3.53 (OD)a | CVVHDF; pre-dilution; 125 | Standard PRISMA M-100 AN69 |
H: 14 (8/6)/43 | H: 63.9 ± 21.2a | H: 9.42 ± 2.31 (OD)a | |||||
Tiranathanagul et al. [32] (2011; TH) | Adult mixed ICU | Severe hepatitis and cirrhosis, hypercalcaemia, Contraindication to citrate or heparin, other therapeutic anticoagulation | C: 10 (5/5)/NR | C: 69.5(32–78)b | C: 21 (18–29) (APACHE II)b | CVVH; pre-dilution; 120 | 1.5 m2 Polyethersulfone dialyzers |
H: 10 (7/3)/NR | H: 75.5 (18–87)b | H: 22 (15–29) (APACHE II)b | |||||
Hetzel et al. [33] (2011; DE) | Nine different ICUs | Contraindication to citrate or heparin, metabolic, alkalosis, pregnancy or lactation, chronic dialysis, other therapeutic, anticoagulation, HIT | C: 87 (57/30)/NR | C: 62 ± 15.3a | C: 21.8 ± 5.1 (APACHE II) | CVVH; pre-dilution; HF-solution flow 3:1 | AV600S high-flux membrane |
9.95 ± 2.9 (SOFA)a | |||||||
H: 83 (59/24)/NR | H: 65 ± 12.5a | H: 22.04 ± 5.5 (APACHE II) | |||||
9.95 ± 2.6 (SOFA)a |